Evidence map›Paper›PMID 41778239›Full record

ArticleCancer diagnosis & prognosis

A Sequential Proteomic Relay Defines a Decade-long Pre-diagnostic Window for Pancreatic Cancer.

Steven Lehrer, Peter H Rheinstein

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Steven LehrerDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Peter H RheinsteinSevern Health Solutions, Severna Park, MD, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Pancreatic adenocarcinoma is characterized by late-stage presentation and high mortality, largely due to the absence of biomarkers that signal disease during its prolonged preclinical phase. The aim of this study was to identify and temporally characterize circulating proteomic biomarkers that undergo systematic change years before clinical diagnosis, and to determine whether these trajectories define discrete pre-diagnostic risk windows that could enable earlier, biologically informed interception. Materials and Methods: Using longitudinal proteomic data from the UK Biobank, we employed hinge-regression change-point modeling to identify temporal inflection points for circulating proteins. We partitioned the pre-diagnostic period into "Far" (5-10 years) and "Near" (0-5 years) windows to evaluate discriminatory performance. Results: We identified a sequential "relay" of protein trajectories. CTHRC1 serves as a primary early-warning signal with an inflection point 8.93 years prior to diagnosis. This is followed by a secondary rise in RELT at 2 years. The integrated proteomic model achieved an Adjusted R Conclusion: Pancreatic cancer is characterized by a predictable, decade-long proteomic countdown. This staged relay model provides a biologically grounded framework for risk-stratified surveillance, extending the window for clinical action far beyond current standards.

Indexed as

biomarker trajectoriesearly cancer detectionPancreatic ductal adenocarcinomaplasma proteomicsUK Biobank

Identifiers

PMID41778239
PMCPMC12951365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.